Massimo Group Trading Halted Due to Volatility Trading Pause
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Massimo Group trading halted, volatility trading pause
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MASI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MASI
Wall Street analysts forecast MASI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MASI is 188.40 USD with a low forecast of 162.00 USD and a high forecast of 210.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 136.250
Low
162.00
Averages
188.40
High
210.00
Current: 136.250
Low
162.00
Averages
188.40
High
210.00
About MASI
Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Clairity Appoints New CEO to Drive AI Breast Cancer Risk Assessment
- Leadership Change: Clairity has appointed founder Dr. Connie Lehman as CEO and Joe Kiani as Chairman of the Board, marking a pivotal moment for the company following FDA De Novo authorization, aimed at accelerating clinical adoption and market expansion.
- Technological Innovation: Clairity's AI risk prediction platform, now FDA-authorized, extracts personalized risk assessments from routine mammograms, which is expected to significantly enhance the effectiveness of breast cancer screening and promote early disease prevention.
- Growing Market Demand: With increasing demand from health systems for Clairity's technology, the company is actively engaging with public and private sector stakeholders, planning to scale deployment across the U.S. to enhance accessibility and personalization of healthcare services.
- Industry Leadership: Dr. Connie Lehman, a globally recognized leader in breast cancer screening and imaging, will drive Clairity's innovation in personalized risk assessment, positioning the company to lead in the future of breast cancer screening and prevention.
Continue Reading
Masimo to Participate in J.P. Morgan 2026 Healthcare Conference
- Conference Participation: Masimo will participate in the J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 PM Pacific Time, showcasing its latest advancements in medical technology to enhance visibility and trust among investors.
- Live Webcast: The presentation will be available via live webcast on Masimo's website, ensuring global investors can access real-time company information, thereby increasing transparency and attracting potential investors' attention.
- Showcasing Technological Strength: Masimo is renowned for its innovative monitoring technologies, particularly its SET® pulse oximetry, which serves over 200 million patients annually worldwide, demonstrating its leadership and market impact in the healthcare sector.
- Industry Recognition: Masimo's pulse oximetry is the primary device at all top 10 U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing, further solidifying its competitive advantage in the high-end medical market.
Continue Reading